Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $11,446.40 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 35,770 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $0.32, for a total value of $11,446.40. Following the completion of the sale, the director directly owned 107,429 shares in the company, valued at approximately $34,377.28. The trade was a 24.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Tuesday, July 7th, Luke Evnin sold 107,429 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.31, for a total transaction of $33,302.99.
• On Tuesday, June 9th, Luke Evnin sold 76,928 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $28,463.36.
• On Monday, June 8th, Luke Evnin sold 60,547 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total transaction of $24,218.80.
• On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total transaction of $9,978.40.
• On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.44, for a total transaction of $8,831.68.
• On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.42, for a total value of $12,494.58.
• On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total value of $13,317.75.
• On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $37,815.73.
• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $14,650.20.
• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total value of $12,741.08.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock opened at $0.40 on Friday. The business’s fifty day moving average is $0.44 and its 200 day moving average is $0.63. Werewolf Therapeutics, Inc. has a one year low of $0.27 and a one year high of $2.38. The stock has a market capitalization of $19.59 million, a PE ratio of -0.32 and a beta of 0.30.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. As a group, sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of large investors have recently made changes to their positions in HOWL. Regal Investment Advisors LLC increased its holdings in shares of Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after purchasing an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. boosted its stake in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics in the 2nd quarter valued at $48,000. AQR Capital Management LLC acquired a new stake in shares of Werewolf Therapeutics in the 1st quarter worth $79,000. Finally, Bridgeway Capital Management LLC increased its stake in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares during the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on HOWL shares. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings cut shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.